Bio stocks on road to recovery
Justin Bailey
6 October 2010
Australian Financial Review
According to Sebastian Evans, fund manager at Naos Asset Management, four of five biotechnology stocks could end up turning into billion-dollar companies. Eli Lilly, Roche and Pfizer are companies to watch, with patents for their wonder drugs Viagra and Zoloft set to expire - forcing them to scour the world for a new product. Mr Evans likes Acrux, Nanosonics and ImpediMed as well, with ImpediMed a particular favourite among brokers. Nanosonics is currently waiting for approval from the US Food and Drug Administration for its Trophon EPA product. The firm has also secured a distribution agreement with General Electric?s health division and has a "buy" recommendation from the one broker covering the stock. Acrux is looking to move into AndroGel?s US market and has a implied 44 per cent return over the next year according to broker target price estimates.
a glowing endorsement for axiron, page-2
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
-0.002(2.53%) |
Mkt cap ! $22.38M | |||
| Open | High | Low | Value | Volume |
| 7.8¢ | 7.9¢ | 7.7¢ | $12.27K | 156.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10092 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 9000 | 1 |
View Market Depth
| Last trade - 15.49pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
-0.002 ( 2.53 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.8¢ | 7.7¢ | 37473 | ||
| Last updated 12.58pm 14/06/2024 ? | |||||
| ACR (ASX) Chart |